Physician profile
Michelle Taylor
NPI 1023469244
$13,022.65
in general payments reported to CMS, 2019-2025
39 companies · $3,004 in 2025
The $3,004 reported for 2025 was more than what 97% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,720 · 2022: $2,805 · 2023: $2,846 · 2024: $2,648 · 2025: $3,004.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,271 · Education: $228.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,270.81 |
| Education | $227.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,901.17 | 2021-2025 | Fasenra, Tezspire, Breztri |
| Glaxosmithkline, LLC. | $1,765.98 | 2021-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $960.15 | 2021-2025 | Ofev, Jascayd, Spiriva Respimat |
| Regeneron Healthcare Solutions, INC. | $904.69 | 2021-2025 | Dupixent |
| Grifols USA, LLC | $704.23 | 2021-2025 | Prolastin-C Liquid |
| United Therapeutics Corporation | $647.46 | 2022-2025 | Tyvaso, Tyvaso, Orenitram |
| Genzyme Corporation | $582.24 | 2021-2025 | |
| Actelion Pharmaceuticals US, INC. | $550.00 | 2021-2025 | Uptravi, Opsumit, Opsynvi |
| Takeda Pharmaceuticals U.S.A., INC. | $428.02 | 2022-2025 | Glassia |
| Mylan Specialty L.P. | $413.79 | 2021-2024 | Yupelri |
| Baxter Healthcare | $387.13 | 2022-2025 | Hillrom - Life 2000 Ventilation System, Hillrom - Vest System Model 105 Home Care |
| Mallinckrodt Hospital Products INC. | $355.82 | 2022-2025 | Acthar |
| Merck Sharp & Dohme LLC | $336.41 | 2021-2025 | Winrevair, Keytruda, Dificid |
| Electromed, INC. | $269.74 | 2022-2025 | Smartvest |
| Verona Pharma, INC. | $191.63 | 2025 | Ohtuvayre |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $186.90 | 2021-2023 | Xarelto |
| Ani Pharmaceuticals, INC. | $178.64 | 2024-2025 | Purified Cortrophin Gel |
| Amgen INC. | $142.87 | 2022-2025 | Tezspire |
| Gilead Sciences, INC. | $134.69 | 2021-2023 | Veklury |
| Insmed, INC. | $132.75 | 2024-2025 | Arikayce |
| W. L. Gore & Associates, INC. | $109.23 | 2023-2024 | Excluder Conformable Aaa Endoprosthesis With Active Control |
| Imperative Care, INC | $106.02 | 2025 | Prodigy Catheter, Hotshot Controller |
| Atricure, INC. | $97.45 | 2021-2025 | Atriclip Laa Exclusion System |
| Philips North America LLC | $94.14 | 2023-2025 | Vest Therapy Und |
| Bayer Healthcare Pharmaceuticals INC. | $78.81 | 2023-2024 | |
| Viatris Specialty LLC | $51.95 | 2025 | Yupelri |
| Integra Lifesciences Corporation | $46.55 | 2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Alexion Pharmaceuticals, INC. | $38.30 | 2022 | |
| Paratek Pharmaceuticals, INC. | $34.83 | 2021-2024 | Nuzyra |
| Pfizer INC. | $34.57 | 2021-2023 | |
| Nabriva Therapeutics, Plc | $21.70 | 2021 | |
| Caris Mpi, INC. | $20.67 | 2025 | Mi Cancer Seek |
| Pinnacle Biologics, INC | $19.85 | 2022 | |
| Astellas Pharma US INC | $18.98 | 2023 | Cresemba |
| Advanced Respiratory, INC | $17.07 | 2021 | |
| Genentech USA, INC. | $15.79 | 2022 | |
| La Jolla Pharmaceutical Company | $14.95 | 2023 | Giapreza |
| Pulmonx Corporation | $13.94 | 2025 | Chartis Catheter, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Lilly USA, LLC | $13.54 | 2025 | Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.